198 related articles for article (PubMed ID: 25189542)
1. Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics.
Gridling M; Ficarro SB; Breitwieser FP; Song L; Parapatics K; Colinge J; Haura EB; Marto JA; Superti-Furga G; Bennett KL; Rix U
Mol Cancer Ther; 2014 Nov; 13(11):2751-62. PubMed ID: 25189542
[TBL] [Abstract][Full Text] [Related]
2. Polypharmacology-based ceritinib repurposing using integrated functional proteomics.
Kuenzi BM; Remsing Rix LL; Stewart PA; Fang B; Kinose F; Bryant AT; Boyle TA; Koomen JM; Haura EB; Rix U
Nat Chem Biol; 2017 Dec; 13(12):1222-1231. PubMed ID: 28991240
[TBL] [Abstract][Full Text] [Related]
3. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
4. A miniaturized chemical proteomic approach for target profiling of clinical kinase inhibitors in tumor biopsies.
Chamrád I; Rix U; Stukalov A; Gridling M; Parapatics K; Müller AC; Altiok S; Colinge J; Superti-Furga G; Haura EB; Bennett KL
J Proteome Res; 2013 Sep; 12(9):4005-17. PubMed ID: 23901793
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
Yoshida T; Zhang G; Smith MA; Lopez AS; Bai Y; Li J; Fang B; Koomen J; Rawal B; Fisher KJ; Chen YA; Kitano M; Morita Y; Yamaguchi H; Shibata K; Okabe T; Okamoto I; Nakagawa K; Haura EB
Clin Cancer Res; 2014 Aug; 20(15):4059-4074. PubMed ID: 24919575
[TBL] [Abstract][Full Text] [Related]
6. Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells.
Ctortecka C; Palve V; Kuenzi BM; Fang B; Sumi NJ; Izumi V; Novakova S; Kinose F; Remsing Rix LL; Haura EB; Koomen JM; Rix U
Mol Cell Proteomics; 2018 Dec; 17(12):2434-2447. PubMed ID: 30217950
[TBL] [Abstract][Full Text] [Related]
7. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer.
Li J; Rix U; Fang B; Bai Y; Edwards A; Colinge J; Bennett KL; Gao J; Song L; Eschrich S; Superti-Furga G; Koomen J; Haura EB
Nat Chem Biol; 2010 Apr; 6(4):291-9. PubMed ID: 20190765
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the promiscuous nature of tyrosine kinase inhibitors assessed in A431 epidermoid carcinoma cells by both chemical- and phosphoproteomics.
Giansanti P; Preisinger C; Huber KV; Gridling M; Superti-Furga G; Bennett KL; Heck AJ
ACS Chem Biol; 2014 Jul; 9(7):1490-8. PubMed ID: 24804581
[TBL] [Abstract][Full Text] [Related]
9. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.
Wu X; Zahari MS; Ma B; Liu R; Renuse S; Sahasrabuddhe NA; Chen L; Chaerkady R; Kim MS; Zhong J; Jelinek C; Barbhuiya MA; Leal-Rojas P; Yang Y; Kashyap MK; Marimuthu A; Ling M; Fackler MJ; Merino V; Zhang Z; Zahnow CA; Gabrielson E; Stearns V; Roa JC; Sukumar S; Gill PS; Pandey A
Oncotarget; 2015 Oct; 6(30):29143-60. PubMed ID: 26356563
[TBL] [Abstract][Full Text] [Related]
10. Serum caveolin-1, a biomarker of drug response and therapeutic target in prostate cancer models.
Tahir SA; Kurosaka S; Tanimoto R; Goltsov AA; Park S; Thompson TC
Cancer Biol Ther; 2013 Feb; 14(2):117-26. PubMed ID: 23114714
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
12. Phosphosignature predicts dasatinib response in non-small cell lung cancer.
Klammer M; Kaminski M; Zedler A; Oppermann F; Blencke S; Marx S; Müller S; Tebbe A; Godl K; Schaab C
Mol Cell Proteomics; 2012 Sep; 11(9):651-68. PubMed ID: 22617229
[TBL] [Abstract][Full Text] [Related]
13. Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib.
Hülsmann HJ; Rolff J; Bender C; Jarahian M; Korf U; Herwig R; Fröhlich H; Thomas M; Merk J; Fichtner I; Sültmann H; Kuner R
Lung Cancer; 2014 Nov; 86(2):151-7. PubMed ID: 25240516
[TBL] [Abstract][Full Text] [Related]
14. Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors.
Schweppe DK; Rigas JR; Gerber SA
J Proteomics; 2013 Oct; 91():286-96. PubMed ID: 23911959
[TBL] [Abstract][Full Text] [Related]
15. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.
Carretero J; Shimamura T; Rikova K; Jackson AL; Wilkerson MD; Borgman CL; Buttarazzi MS; Sanofsky BA; McNamara KL; Brandstetter KA; Walton ZE; Gu TL; Silva JC; Crosby K; Shapiro GI; Maira SM; Ji H; Castrillon DH; Kim CF; García-Echeverría C; Bardeesy N; Sharpless NE; Hayes ND; Kim WY; Engelman JA; Wong KK
Cancer Cell; 2010 Jun; 17(6):547-59. PubMed ID: 20541700
[TBL] [Abstract][Full Text] [Related]
16. The target landscape of clinical kinase drugs.
Klaeger S; Heinzlmeir S; Wilhelm M; Polzer H; Vick B; Koenig PA; Reinecke M; Ruprecht B; Petzoldt S; Meng C; Zecha J; Reiter K; Qiao H; Helm D; Koch H; Schoof M; Canevari G; Casale E; Depaolini SR; Feuchtinger A; Wu Z; Schmidt T; Rueckert L; Becker W; Huenges J; Garz AK; Gohlke BO; Zolg DP; Kayser G; Vooder T; Preissner R; Hahne H; Tõnisson N; Kramer K; Götze K; Bassermann F; Schlegl J; Ehrlich HC; Aiche S; Walch A; Greif PA; Schneider S; Felder ER; Ruland J; Médard G; Jeremias I; Spiekermann K; Kuster B
Science; 2017 Dec; 358(6367):. PubMed ID: 29191878
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
Tang N; Zhang Q; Fang S; Han X; Wang Z
Oncotarget; 2017 Feb; 8(6):9134-9143. PubMed ID: 27852073
[TBL] [Abstract][Full Text] [Related]
18. IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.
Lu H; Wang L; Gao W; Meng J; Dai B; Wu S; Minna J; Roth JA; Hofstetter WL; Swisher SG; Fang B
Mol Cancer Ther; 2013 Dec; 12(12):2864-73. PubMed ID: 24130049
[TBL] [Abstract][Full Text] [Related]
19. Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes.
Estrada-Bernal A; Le AT; Doak AE; Tirunagaru VG; Silva S; Bull MR; Smaill JB; Patterson AV; Kim C; Liu SV; Doebele RC
Clin Cancer Res; 2021 Mar; 27(5):1463-1475. PubMed ID: 33355298
[TBL] [Abstract][Full Text] [Related]
20. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
[No Abstract] [Full Text] [Related]
[Next] [New Search]
